Characterization of Drug-Resistant Influenza A(H7N9) Variants Isolated From an Oseltamivir-Treated Patient in Taiwan

The R292K Mutation That Confers Resistance to Neuraminidase Inhibitors Leads to Competitive Fitness Loss of A/Shanghai/1/2013 (H7N9) Influenza Virus in Ferrets

(2014) Hui-Ling Yen et al.   JOURNAL OF INFECTIOUS DISEASES

Amino Acid Substitutions in Polymerase Basic Protein 2 Gene Contribute to the Pathogenicity of the Novel A/H7N9 Influenza Virus in Mammalian Hosts

(2014) C. K. P. Mok et al.   JOURNAL OF VIROLOGY

Differences in the Pathogenicity and Inflammatory Responses Induced by Avian Influenza A/H7N9 Virus Infection in BALB/c and C57BL/6 Mouse Models

(2014) Guangyu Zhao et al.   PLoS One

Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K

(2013) Chinh Tran-To Su et al.   BMC BIOINFORMATICS

Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses

(2013) Yan Wu et al.   CELL RESEARCH

Virological, Serological, and Antiviral Studies in an Imported Human Case of Avian Influenza A(H7N9) Virus in Taiwan

(2013) Pi-Han Lin et al.   CLINICAL INFECTIOUS DISEASES

Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient

(2013) Aeron C. Hurt et al.   Influenza and Other Respiratory Viruses

Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011–2012 influenza season in Italy

(2013) A. Piralla et al.   JOURNAL OF CLINICAL VIROLOGY

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study

(2013) F. M. Marty et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus In Vitro, in Mice and in Ferrets

(2013) Y. Abed et al.   JOURNAL OF VIROLOGY

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance

(2013) Yunwen Hu et al.   LANCET

The first case of H7N9 influenza in Taiwan

(2013) Sui-Yuan Chang et al.   LANCET

Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome

(2013) Yu Chen et al.   LANCET

Characterization of H7N9 influenza A viruses isolated from humans

(2013) Tokiko Watanabe et al.   NATURE

Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus

(2013) Rongbao Gao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China

(2013) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus

(2013) Yuhua Qi et al.   VIRUS RESEARCH

Resistance to Neuraminidase Inhibitors Conferred by an R292K Mutation in a Human Influenza Virus H7N9 Isolate Can Be Masked by a Mixed R/K Viral Population

(2013) H.- L. Yen et al.   mBio

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility

(2013) Rong Hai et al.   Nature Communications

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods

(2012) Ha T Nguyen et al.   ANTIVIRAL THERAPY

Peramivir for the treatment of influenza

(2012) Avinash K Shetty et al.   Expert Review of Anti-Infective Therapy

Combinatorial Effect of Two Framework Mutations (E119V and I222L) in the Neuraminidase Active Site of H3N2 Influenza Virus on Resistance to Oseltamivir

(2011) Mathilde Richard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Two mutations in the C-terminal domain of influenza virus RNA polymerase PB2 enhance transcription by enhancing cap-1 RNA binding activity

(2011) Shijian Zhang et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Frequency of Drug-resistant Viruses and Virus Shedding in Pediatric Influenza Patients Treated With Neuraminidase Inhibitors

(2011) Daisuke Tamura et al.   CLINICAL INFECTIOUS DISEASES

Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

(2010) N. Sugaya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance

(2010) M. Okomo-Adhiambo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The I222V Neuraminidase Mutation Has a Compensatory Role in Replication of an Oseltamivir-Resistant Influenza Virus A/H3N2 E119V Mutant

(2010) P. Simon et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Herc5 Attenuates Influenza A Virus by Catalyzing ISGylation of Viral NS1 Protein

(2010) Y. Tang et al.   JOURNAL OF IMMUNOLOGY

Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses

(2010) Mariana Baz et al.   JOURNAL OF INFECTIOUS DISEASES

MultiDrug-Resistant 2009 Pandemic Influenza A(H1N1) Viruses Maintain Fitness and Transmissibility in Ferrets

(2010) Matthew J. Memoli et al.   JOURNAL OF INFECTIOUS DISEASES

Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models

(2010) C. W. Seibert et al.   JOURNAL OF VIROLOGY

ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells

(2010) C. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses

(2009) A. C. Hurt et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY